New method for characterising liposome formulated drugs
CF3 coupled with UV-Vis detection able to separate and quantify the amount of free drug in a liposome-drug product.
Postnova Analytics has published an application study that describes a new method for quantification of liposome encapsulated drug using Centrifugal Field-Flow Fractionation (CF3).
Nanoparticles, including liposomes, are increasingly used for delivery of drug molecules. During formulation of a liposome around a drug particle, a relatively large amount of free drug may remain unencapsulated and therefore not available for drug delivery via the liposomal carrier. For formulation groups adopting this drug delivery methodology it is important to quantify the amount of free versus encapsulated drug in a product to accurately determine the delivered dose of drug to a patient.
In this study, CF3 coupled with UV-Vis detection was shown to be able to separate and quantify the amount of free drug in a liposome-drug product. The separation data was verified using optical microscopy. The authors conclude that CF3 shows great promise for separation and quantification of drug particles, as the field of nanomedicine and liposomal drug delivery grows.
The Postnova CF2000 Series system is based on the CF3 principle using a centrifugal field as the driving force for the separation. Particles effected by this field are separated by dynamic diffusion based upon both their size and density. This unique feature allows researchers to separate different particle materials having the same particle size. The separation can be further optimized by the use of different eluents and rotation speed programs. The CF2000 has shown great utility for the separation of complex nanoparticle samples in application areas including pharmaceuticals, environmental research, food, cosmetics and agrochemicals.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.